Sun Pharmaceutical Industries, India’s largest drug maker, announced plans to invest ₹500 crore in a new pharmaceutical manufacturing plant in Assam. This project is expected to create over 500 direct employment opportunities in phases. The announcement saw Sun Pharma shares trading nearly 1% higher on Thursday, February 5. The proposal for establishing pharmaceutical manufacturing facilities in Assam was discussed during a meeting between senior Sun Pharma officials and Ravi Kota, Chief Secretary of Assam. Sun Pharma was represented by Rahul Awasthi, Senior Vice President, and Ranjit Mohapatra, Associate Vice President.The investment proposal includes the establishment of drug formulation manufacturing units in Assam, primarily catering to the Indian market. The total investment is ₹500+ crore, to be implemented in two phases. Over 500 direct jobs are expected to be generated once operations commence.
Dr. Kota added that the project is expected to significantly boost local employment once operational.
Discussions during the meeting covered critical factors for successful project execution, including land availability, water and power supply, connectivity, and access to skilled manpower. Sun Pharma also emphasized its commitment to sustainable manufacturing practices. These include efficient water usage, greater adoption of renewable energy, and responsible waste management. These initiatives align with environmental norms and regulatory standards.
According to Dr. Kota, the meeting forms part of the Assam government’s ongoing engagement with prospective investors. This engagement is aimed at promoting employment generation, inclusive development, and long-term economic growth in the state.
Sun Pharma is the world’s fourth-largest pharmaceutical company and the largest in India. The company operates over 40 manufacturing facilities across five continents. It has a presence in over 100 countries worldwide.
In related financial developments, Sun Pharma reported a 16% year-on-year rise in consolidated net profit for Q3 FY26, which ended December 31, 2025. The net profit stood at ₹3,369 crore, compared to ₹2,903 crore in Q3 FY25. Revenue from operations was ₹15,520 crore in Q3 FY26, an increase from ₹13,675 crore a year earlier. The company’s board has also approved an interim dividend of ₹11 per equity share for the financial year 2025–26.
Sun Pharma’s planned Assam investment reinforces the state’s growing appeal as a pharmaceutical manufacturing destination. It also supports India’s broader goals of industrial expansion, job creation, and sustainable growth. The project is expected to play a key role in strengthening Assam’s industrial ecosystem and healthcare manufacturing capacity.
Leave a Reply